Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GH Guardant Health	$63.50 +0.1%	$50.79	$20.14 ▼ $64.70	$7.92B	1.43	2.38 million shs	1.67 million shs
HIMS Hims & Hers Health	$44.07 -2.8%	$51.10	$13.47 ▼ $72.98	$9.96B	2.08	33.52 million shs	19.79 million shs
NTRA Natera	$163.04 -1.6%	$154.70	$110.57 ▼ $183.00	$22.38B	1.76	1.50 million shs	752,766 shs
VCYT Veracyte	$28.61 -1.6%	$26.70	$22.61 ▼ $47.32	$2.25B	1.97	1.16 million shs	1.04 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GH Guardant Health	+2.50%	+8.30%	+42.80%	+66.09%	+137.21%
HIMS Hims & Hers Health	+5.75%	+7.89%	-20.86%	-14.85%	+183.60%
NTRA Natera	+1.99%	+3.49%	+19.30%	+2.79%	+40.30%
VCYT Veracyte	-1.62%	-1.69%	+15.13%	+8.79%	-10.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GH Guardant Health	3.2835 of 5 stars	1.5	2.0	4.4	3.4	2.5	0.6
HIMS Hims & Hers Health	2.7265 of 5 stars	2.0	3.0	0.0	3.0	3.3	1.9
NTRA Natera	3.1194 of 5 stars	3.5	3.0	0.0	3.0	2.5	0.6
VCYT Veracyte	2.3978 of 5 stars	3.4	0.0	4.3	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GH Guardant Health	3.06	Buy	$57.50	-9.45% Downside
HIMS Hims & Hers Health	1.92	Reduce	$38.92	-11.69% Downside
NTRA Natera	3.06	Buy	$193.19	18.49% Upside
VCYT Veracyte	2.70	Moderate Buy	$40.90	42.96% Upside

Current Analyst Ratings Breakdown

Latest GH, VCYT, NTRA, and HIMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	HIMS Hims & Hers Health	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$48.00 ➝ $37.00
8/15/2025	NTRA Natera	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$183.00
8/11/2025	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$210.00 ➝ $220.00
8/10/2025	NTRA Natera	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$195.00
8/8/2025	VCYT Veracyte	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Underweight ➝ Underweight	$28.00
8/8/2025	NTRA Natera	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	NTRA Natera	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$190.00 ➝ $210.00
8/8/2025	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$251.00 ➝ $255.00
8/5/2025	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/31/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$57.00 ➝ $60.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GH Guardant Health	$739.02M	10.72	N/A	N/A	($2.45) per share	-25.92
HIMS Hims & Hers Health	$1.48B	6.75	$0.36 per share	122.07	$2.49 per share	17.70
NTRA Natera	$1.96B	11.39	N/A	N/A	$9.08 per share	17.96
VCYT Veracyte	$445.76M	5.05	$1.00 per share	28.50	$15.52 per share	1.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GH Guardant Health	-$436.37M	-$3.35	N/A	N/A	N/A	-49.93%	N/A	-28.95%	11/5/2025 (Estimated)
HIMS Hims & Hers Health	$126.04M	$0.80	55.09	84.75	2.90	9.63%	26.26%	13.06%	11/3/2025 (Estimated)
NTRA Natera	-$190.43M	-$1.91	N/A	N/A	N/A	-12.89%	-22.22%	-15.03%	11/11/2025 (Estimated)
VCYT Veracyte	$24.14M	$0.33	86.70	39.74	N/A	5.50%	6.07%	5.53%	11/5/2025 (Estimated)

Latest GH, VCYT, NTRA, and HIMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NTRA Natera	-$0.60	-$0.74	-$0.14	-$0.74	$476.84 million	$546.60 million
8/4/2025	Q2 2025	HIMS Hims & Hers Health	$0.18	$0.17	-$0.01	$0.17	$550.06 million	$544.83 million
7/30/2025	Q2 2025	GH Guardant Health	-$0.52	-$0.44	+$0.08	-$0.80	$211.19 million	$232.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GH Guardant Health	N/A	3.71	3.35
HIMS Hims & Hers Health	1.72	4.98	4.46
NTRA Natera	N/A	3.72	3.58
VCYT Veracyte	N/A	5.43	5.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GH Guardant Health	92.60%
HIMS Hims & Hers Health	63.52%
NTRA Natera	99.90%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
GH Guardant Health	6.10%
HIMS Hims & Hers Health	17.71%
NTRA Natera	5.63%
VCYT Veracyte	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GH Guardant Health	2,021	124.71 million	117.10 million	Not Optionable
HIMS Hims & Hers Health	1,637	226.02 million	185.99 million	Optionable
NTRA Natera	4,434	137.25 million	129.52 million	Optionable
VCYT Veracyte	790	78.67 million	77.57 million	Optionable

GH, VCYT, NTRA, and HIMS Headlines

Recent News About These Companies

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

August 27 at 11:25 AM | businesswire.com

Virtus Advisers LLC Acquires Shares of 36,230 Veracyte, Inc. $VCYT

August 27 at 8:25 AM | marketbeat.com

76,342 Shares in Veracyte, Inc. $VCYT Acquired by Campbell & CO Investment Adviser LLC

August 27 at 7:13 AM | marketbeat.com

Invesco Ltd. Lowers Position in Veracyte, Inc. $VCYT

August 27 at 3:30 AM | marketbeat.com

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

August 26 at 7:56 PM | finance.yahoo.com

Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

August 26 at 10:18 AM | seekingalpha.com

Is the Options Market Predicting a Spike in Veracyte Stock?

August 25 at 10:11 AM | zacks.com

How Investors May Respond To Veracyte (VCYT) Earnings Upgrades and Spotlight as a Momentum Stock

August 24 at 11:10 AM | finance.yahoo.com

Advantage Alpha Capital Partners LP Has $779,000 Stake in Veracyte, Inc. $VCYT

August 24 at 7:37 AM | marketbeat.com

Wellington Management Group LLP Has $114.25 Million Stake in Veracyte, Inc. $VCYT

August 24 at 5:01 AM | marketbeat.com

Charles Schwab Investment Management Inc. Has $21.96 Million Stake in Veracyte, Inc. $VCYT

August 24 at 3:18 AM | marketbeat.com

Craig-Hallum Sticks to Its Buy Rating for Veracyte (VCYT)

August 23, 2025 | theglobeandmail.com

Craig-Hallum Remains a Buy on Veracyte (VCYT)

August 23, 2025 | theglobeandmail.com

Deutsche Bank AG Sells 9,272 Shares of Veracyte, Inc. $VCYT

August 23, 2025 | marketbeat.com

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

August 22, 2025 | zacks.com

15,400 Shares in Veracyte, Inc. $VCYT Acquired by Northwest & Ethical Investments L.P.

August 22, 2025 | marketbeat.com

Veracyte's Market Outlook Divides Major Investors

August 20, 2025 | aktiencheck.deA

EverSource Wealth Advisors LLC Acquires 15,832 Shares of Veracyte, Inc. $VCYT

August 20, 2025 | marketbeat.com

Vanguard Group Inc. Increases Holdings in Veracyte, Inc. $VCYT

August 20, 2025 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Lord Abbett & CO. LLC

August 19, 2025 | marketbeat.com

Nuveen LLC Purchases New Position in Veracyte, Inc. (NASDAQ:VCYT)

August 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GH, VCYT, NTRA, and HIMS Company Descriptions

Guardant Health NASDAQ:GH

$63.50 +0.07 (+0.11%)

Closing price 04:00 PM Eastern

Extended Trading

$63.50 0.00 (0.00%)

As of 05:42 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Hims & Hers Health NYSE:HIMS

$44.07 -1.28 (-2.82%)

Closing price 03:59 PM Eastern

Extended Trading

$44.18 +0.11 (+0.25%)

As of 06:04 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Natera NASDAQ:NTRA

$163.04 -2.67 (-1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$162.36 -0.68 (-0.42%)

As of 05:48 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Veracyte NASDAQ:VCYT

$28.61 -0.46 (-1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$28.45 -0.16 (-0.56%)

As of 05:58 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time